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INTRODUCTION
Hypouricemia is generally defined as a serum uric acid 
(SUA) concentration of less than 2.0 mg/dL [1]. It has 
no recognizable symptoms that require treatment. It 
is characterized by increased uric acid clearance or de-
creased uric acid production [1,2]. While hyperuricemia 
and gout are significant health concerns and have been 
the subject of a large number of studies [3,4], less atten-
tion has been paid to hypouricemia, even though it is 
clinically important. Nonetheless, interest in hypourice-
mia has begun to increase, due to a better understanding 
of the role of uric acid transporters. The human urate 
transporter 1 (URAT1) and human glucose transporter-
like protein 9 (GLUT9) are two representative renal urate 
transporters [2,5-11]. A genetic defect in these two urate 
transporters is responsible for idiopathic hypouricemia.
The reported prevalence of hypouricemia has varied 
in previous studies, depending on the type of study 
subject and the definition of hypouricemia [5,12-20]. 
Some studies have reported that it was between 0.15% 
and 3.30% in the general population and in outpatients 
and between 1.24% and 2.54% in hospitalized patients. 
A higher prevalence of hypouricemia has been found 
among inpatients than among outpatients. In addi-
tion to a genetic defect of the renal urate transporter, 
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Background/Aims: We aimed to investigate the prevalence and possible causes of 
hypouricemia in the Korean population and to compare our findings with pub-
lished results of other populations.
Methods: We examined the serum uric acid levels of 30,757 subjects who had their 
uric acid values measured at least once during a 1-year period. All individuals 
with hypouricemia (serum uric acid < 2.0 mg/dL, n = 424) were reviewed with re-
spect to medical drug history and concomitant diseases previously identified as 
being associated with hypouricemia.
Results: The prevalence of hypouricemia was 4.14% (299/7,223) among inpa-
tients and 0.53% (125/23,534) among outpatients, for an overall prevalence of 1.39% 
(424/30,757). Possible causes associated with hypouricemia were found to be solid 
or hematologic malignancies (n = 86), diabetes mellitus (n = 56), and therapeutic 
drugs (n = 29). The medications were allopurinol (n = 11), angiotensin II receptor 
blockers (n = 10), salicylates (n = 6), febuxostat (n = 1), and warfarin (n = 1). In the 
remaining 226 individuals, the cause of hypouricemia was not identified.
Conclusions: Hypouricemia is relatively common in the Korean population com-
pared to those of other countries. The possible causes associated with hypourice-
mia are related to underlying diseases and medications.
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enhanced uric acid excretion due to medical diseases or 
medications can also result in hypouricemia [1]. 
The prevalence of hypouricemia has not been investi-
gated previously in Korea and few studies have focused 
on the factors affecting hypouricemia in the Korean 
population. Therefore, we aimed to investigate the prev-
alence and possible causes of hypouricemia in the Ko-
rean population and to compare our findings with those 
reported for other populations.
METHODS
Population sample
A total of 48,613 SUA values were obtained from patients 
who visited a tertiary care hospital for medical treat-
ment or a checkup during the period January to Decem-
ber 2012. In these 12 months 30,757 patients received at 
least one SUA test, and 7,223 patients had the test while 
they were hospitalized. Although 24,970 subjects visit-
ed the outpatient clinic, the number of outpatients was 
calculated as 23,534 because those who had already had 
an SUA test while hospitalized during that period were 
excluded if they had the test again as outpatients. If a 
patient had multiple SUA values during the test period, 
if at least one of those values was less than 2.0 mg/dL, 
he/she was classified in the hypouricemia patient group. 
The total number of hypouricemia patients was 424.
SUA levels of the study subjects
The medical information team at the hospital used a 
computer program to record the patients’ SUA levels. 
Hypouricemia was identified as cases in which the SUA 
level was less than 2.0 mg/dL [1,19]. An average of each 
patient’s SUA values was taken as a representative SUA 
value for each patient. However, in the hypouricemia 
group, if a patient only had one SUA value that was less 
than 2.0 mg/dL, that measurement was taken as his/her 
representative value. Moreover, in cases where there 
were more than two values of SUA less than 2.0 mg/dL, 
the values exceeding 2.0 mg/dL were excluded, and only 
those less than 2.0 mg/dL were used for calculating the 
average to obtain the representative value.
Review of possible causes of hypouricemia
The hospitalization records, outpatient medication re-
cords, and underlying diseases of the subjects with hy-
pouricemia were assessed for the 3 months before the 
occurrence of hypouricemia. If there were recorded 
medications from another hospital, they were included 
as etiologies, and the most probable etiologies were se-
lected.
Statistical analysis
Continuous variables, such as the representative SUA 
levels, are expressed as the mean ± standard deviation. 
Categorical variables, such as the cause of hypouricemia, 
are shown as frequencies. Student t test was used to ex-
amine differences in the SUA levels of the subjects with 
hypouricemia. A p value of less than 0.05 was considered 
statistically significant. All statistical analyses were per-
formed using SPSS version 20.0 (IBM Co., Armonk, NY, 
USA).
Ethics statement
This study was approved by the Institutional Review 
Board of Hanyang University Hospital. Informed con-
sent from the patients was not required because we ex-
amined the data retrospectively from medical records 
and de-identified it after collection to ensure patient 
confidentiality.
RESULTS
Characteristics of the study subjects 
Among the 30,757 subjects, 57.6% were female (n = 17,725) 
and 42.4% were male (n = 13,032). The total mean age was 
50.8 ± 15.7 years; the mean age of the female subjects was 
51.5 ± 15.5 years and the mean age of the male subjects 
was 49.9 ± 16.0 years. Mean SUA level was 5.16 ± 1.62 mg/
dL; the mean SUA level of the male subjects (6.05 ± 1.60 
mg/dL) was higher than that of the female subjects (4.50 
± 1.27 mg/dL, p < 0.05).
Prevalence of hypouricemia
The prevalence of hypouricemia among all of the sub-
jects was 1.39% (424/30,757) (Fig. 1). Among the 424 sub-
jects with hypouricemia, 68.4% (n = 290) were female and 
31.6% (n = 134) were male. The prevalence of hypourice-
mia was 4.14% (299/7,223) among inpatients and 0.53% 
(125/23,534) among outpatients, and 1.03% (134/13,032) in 
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male patients and 1.64% (290/17,725) in female patients.
Possible causes associated with hypouricemia
Table 1 presents the possible causes of hypouricemia 
and their rates among the patients enrolled in the study. 
The possible causes were identified as solid or hema-
tologic malignancies (n = 86), diabetes mellitus (n = 56), 
and therapeutic drugs (n = 29). The medications were 
allopurinol (n = 11), angiotensin II receptor blockers (n = 
10), salicylates (n = 6), febuxostat (n = 1), and warfarin (n = 
1). In the remaining 226 individuals, the cause of hypou-
ricemia was not identified.
DISCUSSION
In the present study, the prevalence of hypouricemia 
among Koreans was relatively high, and it was detected 
in inpatients as well as outpatients and healthy groups 
[12-19]. As in other studies, the prevalence of hypouri-
cemia was higher in inpatients than in outpatients or 
healthy people [15,17-19]. According to data collected in 
studies that used a similar definition of hypouricemia, 
the total prevalence rate of hypouricemia among west-
erners varied from 0.61% to 0.97% [13,16]. In Japan, the 
prevalence rate for outpatients and healthy individuals 
ranged between 0.15% and 0.34%, whereas that of inpa-
tients was 2.54% [15,17]. In our study, the total prevalence 
rate was 1.39%, which is higher than that of westerners; 
the prevalence rate of outpatients and checkup patients 
was 0.53%, and that of inpatients was 4.14%. The prev-
alence rates were higher compared to those reported 
for Japanese patients. The prevalence rates are sum-
marized in Table 2. In a previous study, the prevalence 
of hypouricemia among 909 healthy Koreans was 3.3% 
[20]. However, the criterion for hypouricemia in that 
study was less than 3.0 mg/dL, so the results cannot be 
compared with those of our study. Applying the defini-
tion of an SUA value of less than 3.0 mg/dL in our data 
analysis, the prevalence rate was 7.66% (2,355/30,757), 
and even when comparing only the outpatients and 
check-up patients, it was as high as 5.23% (1,306/24,971). 
The prevalence was higher among women than among 
men [12,14,17,20]. This finding is natural, because the 
number of medications or diseases that might trigger 
hypouricemia in inpatients is greater [18], and it is well 
known that the SUAs of premenopausal women are low-
er than men’s [21]. The cause of the higher prevalence 
of hypouricemia among Koreans than among other 
ethnicities is not clear. Although the exact reason is un-
known, it should be associated with genetic differences, 
body weight, and dietary habits. Nevertheless, given the 
prevalence rate, more research and attention must be 
Table 1. Possible causes associated with hypouricemia in 
Korean population
Possible causes No. (%)
Neoplasia 86 (43.4)
Solid 79 (39.9)
Hematologic 7 (3.5)
Diabetes mellitus 56 (28.3)
Therapeutic drugs 29 (14.6)
Allopurinol 11 (5.6)
Angiotensin II receptor blockers 10 (5.1)
Salicylates 6 (3.0)
Febuxostat 1 (0.5)
Warfarin 1 (0.5)
Intracranial disease 18 (9.1)
Obstructive jaundice 7 (3.5)
Renal tubular acidosis 1 (0.5)
Ulcerative colitis 1 (0.5)
Total 198
Figure 1. The prevalence of hypouricemia in total popula-
tion, male, female, inpatient, and outpatient. 
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applied to hypouricemia, considering the great deal of 
interest in hyperuricemia.
Malignancy ranked first as a possible etiology of hy-
pouricemia [22,23], followed by diabetes mellitus and 
concomitant medication [24,25]. The rate of obstructive 
jaundice or liver disease as etiologies was relatively low 
[19]. These results are consistent with previous research 
outcomes. In order to differentiate hypouricemia, a frac-
tional excretion of uric acid (FEUA) is necessary to evalu-
ate renal tubular defects [1,2]. When FEUA is over 10%, it 
is considered that the subject has pathologic uricosuria. 
When FEUA decreases, it means that uric acid produc-
tion has declined, while the reason FEUA increases is 
a decrease in reabsorption or an increase in the renal 
excretion of uric acid. When hypouricemia is detected 
in a hospital, efforts should be made to find the cause. 
Whether there is another disease causing it should also 
be checked; hypouricemia can be a tool for finding un-
derlying disease.
Hypouricemia patients are known to have no symp-
toms, so any symptoms that appear are those of a caus-
ative disease of hypouricemia [1]. According to reports 
on idiopathic renal hypouricemia (iRHUC), patients 
exhibits exercise-induced acute renal failure, urolithia-
sis, and hematuria along with fatigue, nausea, vomiting, 
and diffuse abdominal discomfort as causative diseases 
of hypouricemia [1,2,10,26]. Uric acid is a strong anti-
oxidant, and anaerobic exercise increases oxygen-free 
radicals, which then trigger kidney vasoconstriction and 
reduce the glomerular filtration rate [27]. In Japan, it is 
argued that iRHUC can be found by testing SUA before 
the initiation of a physical education class [26]. In or-
der to diagnose iRHUC, hypouricemia and increased 
FEUA should first be checked [2]. There are two differ-
ent types of genetic defects of the renal urate transporter 
[10,28]. The first type is a defect of the SLC22A12 gene 
encoding in URAT1 [29], and the second type is a defect 
of the SLC2A9 gene encoding GLUT9 [30]. Among the 
424 subjects with hypouricemia in our study, 226 cases 
were of an unknown cause. Unfortunately, only a little 
FEUA was measured during the measurement of SUA, 
and therefore, the possibility of iRHUC was not verified. 
However, it was possible in a considerable number of 
cases. Therefore, when the cause of hypouricemia is un-
clear, efforts to find iRHUC through FEUA and genetic 
testing should be made. Ta
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The present study had some limitations. As men-
tioned earlier, an investigation of test results in a single 
medical institution was conducted. While a previous 
study of Koreans involved 30 hypouricemia patients, this 
study is meaningful because we analyzed the prevalence 
and causes of this disease with a large number of sub-
jects. Second, there might be information missing, such 
as height, weight, and renal function, because this study 
only investigated medical records of medication and co-
morbidities to determine the causes of hypouricemia. 
Interviews with patients, FEUA, and genetic testing will 
all lead to a more precise analysis. Lastly, comparisons 
with other ethnicities with respect to the prevalence of 
hypouricemia and its causes require caution in inter-
pretation, because the results might differ according to 
the prevalence of underlying diseases and the frequency 
of using medication. 
In conclusion, hypouricemia is relatively common in 
the Korean population. The possible causes associated 
with hypouricemia are related to underlying diseases 
and medications. In addition, idiopathic hypouricemia 
seems not to be rare.
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